PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04404361|
Recruitment Status : Recruiting
First Posted : May 27, 2020
Last Update Posted : January 19, 2021
|Condition or disease||Intervention/treatment||Phase|
|COVID19 COVID-19 COVID||Drug: Pacritinib Drug: Placebo||Phase 3|
This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer. Severe COVID-19 is defined as confirmed disease in patients who are hospitalized with hypoxia (blood oxygen saturation [SpO2] ≤93% on room air at sea level), respiratory rate >30, arterial oxygen partial pressure [PaO2]/ fraction of inspired oxygen [FiO2] <300, or lung infiltrates >50% but do not require IMV.
Patients will be randomized 1:1 to receive pacritinib (400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC or placebo + SOC.
Assigned treatment will continue for up to Day 14 or until the patient experiences intolerable adverse events (AEs), withdraws consent, or initiates another investigational therapy or until the study is terminated. Assigned therapy may be given for an additional 7 days (for a total of 21 days) with the approval of the Medical Monitor if, in the opinion of the investigator, the patient's clinical signs and symptoms are improving and the potential benefit outweighs the potential risk.In the event of hospital discharge, patients will complete treatment with the assigned therapy as an outpatient.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||364 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer|
|Actual Study Start Date :||May 22, 2020|
|Estimated Primary Completion Date :||July 31, 2021|
|Estimated Study Completion Date :||October 31, 2021|
Experimental: Pacritinib and SOC
Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC
100 mg capsules
Placebo Comparator: Placebo and SOC
4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC
Placebo capsules matching pacritinib 100 mg capsules
- Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization [ Time Frame: 28 days ]The proportion is calculated as the number of patients who progress divided by the total number of patients in the ITT population.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04404361
|Contact: John Volponefirstname.lastname@example.org|
|Contact: Simran Singhemail@example.com|